# Antipsychotics and Metabolic Harm

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-20 | Updated: 2026-10-30

Canonical page: https://glpwatchdog.org/research/antipsychotics-and-metabolic-harm

> The drugs that work best for schizophrenia are the hardest on metabolism, and switching is often not an option. A Danish trial treated the consequence instead, and measured psychiatric symptoms as an outcome.

## Key points

- No difference in psychiatric symptoms or psychiatric adverse events.
- But 73 people over 26 weeks cannot rule out a rare psychiatric event.
- 43% reached HbA1c <5.4% vs 3% on placebo, a better measure than the −0.25% mean.
- Weight −9.2 kg, waist −7.0 cm, fat mass −6.1 kg versus placebo.
- The trial used 1 mg of semaglutide, the diabetes strength; weight treatment uses 2.4 mg.
- Not an argument to change psychiatric medication.

We covered a first attempt at this question in [COaST](https://glpwatchdog.org/research/glp1-and-antipsychotic-weight-gain), which ended at 31 participants. A second Danish trial has now answered it at more than twice the size, in people taking clozapine *or* olanzapine whose blood sugar had begun to drift. It reports the result this group needs most: metabolic improvement with **no worsening of psychiatric symptoms**.[1]

## What this trial adds

Three things separate it from the earlier work. It is larger: 73 randomized against 31. It includes olanzapine alongside clozapine, widening the question beyond the single hardest case. And it selected for people whose blood sugar had already started to move but who were not yet on any diabetes treatment, which makes it a trial about *prevention* rather than about rescue.

That last point sets up the whole reading of the numbers below. The standard advice, to switch to something metabolically kinder, is unavailable to many of the people who most need it, because these drugs are prescribed when others have failed. Treating the metabolic consequence rather than removing the cause is not a compromise here. It is frequently the only route open, and not one that is reliably offered: across 49 studies, people with diabetes and a mental health diagnosis had [a quarter of the odds of being prescribed a GLP-1](https://glpwatchdog.org/research/a-quarter-as-likely-to-be-offered-it).

## What was done

Across three Danish sites between 2021 and 2024, adults aged 18 to 65 with a schizophrenia spectrum disorder, taking clozapine or olanzapine started within the previous five years, with an HbA1c between 5.4% and 7.4% and no diabetes treatment, were randomized to weekly semaglutide 1 mg or matching placebo for 26 weeks alongside their existing therapy. Of 104 screened, 73 were randomized and 57 (78%) finished. Average age was 35, 65% were women, and average BMI was 36.1.

> **Note the dose: 1 mg.** That is a semaglutide dose used for type 2 diabetes, not the 2.4 mg used for weight management. Anyone setting the weight result below against figures from the obesity trials is comparing different doses as well as different populations.

## What changed

*Semaglutide against placebo at 26 weeks. Differences between groups, with 95% confidence intervals.[1]*

| Outcome | Difference | 95% CI | P |
| --- | --- | --- | --- |
| HbA1c | −0.25% | −0.33 to −0.16 | <.001 |
| Body weight | −9.2 kg | −13.3 to −5.1 | <.001 |
| Waist circumference | −7.0 cm | −10.6 to −3.3 | <.001 |
| Fat mass | −6.1 kg | −10.2 to −1.9 | .006 |

A quarter of a percentage point of HbA1c reads as unimpressive until you look at who was enrolled. Entry required an HbA1c between 5.4% and 7.4% with no diabetes medication, so this was a mostly prediabetic group with very little room to fall. In that setting the proportion crossing into low-risk territory is the better measure, and **43% of the semaglutide group (12 of 28) reached an HbA1c below 5.4%, against 3% on placebo**.

> A small mean difference in a population already near normal is not a small effect.

Lipids, liver function and blood pressure did not differ between groups. That is a reminder that 26 weeks is short for outcomes that move slowly, and that weight loss does not automatically improve everything measurable.

## A third trial, and the mechanism question it answers

HISTORI is the largest of the three. It randomized **154 people** with schizophrenia, prediabetes and excess weight, all taking second-generation antipsychotics, to semaglutide 1.0 mg or placebo for 30 weeks, and 91.5% completed.[2]

*HISTORI at 30 weeks, against placebo.[2]*

| Measure | Effect | P |
| --- | --- | --- |
| Fasting glucose | −0.87 mmol/L (95% CI −1.15 to −0.59) | < 0.001 |
| Insulin sensitivity | +8.60 (5.82 to 13.65) | 0.001 |
| Insulin resistance | −0.69 (−1.00 to −0.20) | 0.006 |
| Weight | −9.2 kg | — |
| **β-cell function** | **+8.10 — a modest increase** | **0.19** |

The 9.2 kg weight loss matches the Danish trial above almost exactly, in a separate population, which is the kind of agreement that makes a result believable.

> **The last row answers a question the other trials could not: the drug is not repairing what the antipsychotics damaged.** β-cell function did not significantly improve, and a mediation analysis attributed the gains in insulin sensitivity and insulin resistance to the *weight loss itself*.

That distinction has a practical edge. If the improvement depends on the weight loss, it depends on the weight loss *persisting*. Everything this register documents about what happens when these drugs stop applies here with particular force, in people who will remain on the antipsychotics that caused the problem.

## The psychiatric result

For someone stable on clozapine, the question is not whether a drug will reduce their weight. It is whether adding it will destabilize an illness that took years to control. The trial found **no difference in psychiatric symptoms** between groups and no difference in psychiatric adverse events. Gastrointestinal effects were common, mild and temporary, as they are everywhere else in this class.

> **Read that reassurance at the size of the trial.** Seventy-three people over 26 weeks can show that adding semaglutide did not commonly worsen psychiatric symptoms. It cannot rule out a rare psychiatric event, and it does not speak to what happens after six months. “No difference observed” in a trial this size is a statement about common effects.

Within that limit it is useful, because the alternative evidence is worse. Much of the public conversation about these drugs and mental health runs on registry signals and anecdote. A randomized trial conducted specifically in people with serious mental illness, measuring psychiatric symptoms as an outcome, is a better instrument than either, even at this size.

## What this does not say

- **It is not an argument to change psychiatric medication.** Clozapine and olanzapine are prescribed when other drugs have failed. Nothing here bears on that decision, which belongs entirely to a psychiatrist.
- **It is 26 weeks.** Antipsychotic-associated metabolic risk accumulates over decades.
- **Everyone had early glycemic changes and no diabetes treatment.** This is prevention in a group heading toward diabetes, not treatment of established disease.
- **It reports no cardiovascular outcomes.** The mortality gap that motivates the whole question is not something a 73-person, six-month trial can address.

For what these drugs do to mood and motivation in other psychiatric settings, see [semaglutide and motivation](https://glpwatchdog.org/research/semaglutide-and-motivation).

## Frequently asked questions

### Can someone on clozapine or olanzapine take a GLP-1?

In this randomized trial, adding weekly semaglutide 1 mg alongside those drugs for 26 weeks improved blood sugar, weight, waist and fat mass, with no difference in psychiatric symptoms or psychiatric adverse events. It remains a decision for the treating psychiatrist.

### Did it make psychiatric symptoms worse?

No difference was observed between the semaglutide and placebo groups in either psychiatric symptoms or psychiatric adverse events. With 73 participants over 26 weeks, that is meaningful evidence about common effects and cannot exclude rare ones.

### The HbA1c difference was only 0.25%. Is that worth having?

Entry required an HbA1c between 5.4% and 7.4% with no diabetes medication, so most participants started near normal and had little room to fall. The more informative figure is that 43% on semaglutide reached an HbA1c below 5.4% against 3% on placebo.

### How much weight did people lose?

9.2 kg more than placebo over 26 weeks, along with 7.0 cm of waist circumference and 6.1 kg of fat mass. That was on the 1 mg dose used for diabetes rather than the 2.4 mg used for weight management.

### Should someone switch antipsychotics instead?

That is a question for a psychiatrist, and for many people it is not available: clozapine and olanzapine are typically prescribed precisely because other drugs did not work. This trial addresses treating the metabolic consequence, not replacing the cause.

## References

1. Sass MR, Klausen MK, Schwarz CR, et al. Semaglutide and Early-Stage Metabolic Abnormalities in Individuals With Schizophrenia Spectrum Disorders: A Randomized Clinical Trial. JAMA Psychiatry. 2026. PMID: 41335431. https://pubmed.ncbi.nlm.nih.gov/41335431/
2. Ganeshalingam AA, Uhrenholt N, Arnfred S, et al. Semaglutide Effects on Insulin Sensitivity and β-Cell Function in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial. Diabetes Care. 2026. PMID: 41778920. https://pubmed.ncbi.nlm.nih.gov/41778920/

---

Cite as: GLP Watchdog, Nora Bissett, "Antipsychotics and Metabolic Harm", published 2026-08-20, updated 2026-10-30. https://glpwatchdog.org/research/antipsychotics-and-metabolic-harm

Canonical HTML page: https://glpwatchdog.org/research/antipsychotics-and-metabolic-harm

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
